The collaboration with Revvity resulted in the launch of their staining kit, tested and approved by ETAP-LAB!
Results of the strategic collaboration between ETAP-Lab and Revvity announced We are proud to announce that ETAP-Lab, preclinical CRO expert in neuroscience, partnered with Revvity, leader in High Content Screening (HCS) solutions, to push the boundaries of discovery by combining their expertise and technology. Revvity has just launched the staining kit for astrocyte differentiation - tested and approved by ETAP-LAB - specially designed for iPSC-derived neuronal models. At ETAP-LAB, our teams contributed to this successful launch thanks to: our neuroscience expertise,
1st Anniversary of the STROK@LLIANCE building’s inauguration!
Exactly one year later
POSTER: „Pro-healing effects of Plasana One®, an argon-generated cold plasma on ischemic skin wounds”
Discover the excellent results on ischemic skin wounds in our Poster: "Pro-healing effects of Plasana One®, an argon-generated cold plasma on ischemic skin wounds”. Presented by Jean-François Bisson at the European Society for Dermatological Research (ESDR 2025, Antwerp, Belgium), featuring results from a client study on our ischemic skin wound model, conducted in collaboration with École Polytechnique, Laboratoire de Physique des Plasmas & Plasana Médical. 💡This study contributed to the preclinical development of the Plasana One® technology, an innovative device which is
Publication on Functional discrimination of CSF from Alzheimer’s patients in a brain on chip platform
Publication: Functional discrimination of CSF from Alzheimer’s patients in a brain on chip platform. Sci Rep 15, 29738 (2025). Authors: Miny, L., Rontard, J., Allouche, A. et al. Affiliated: NETRI (Lyon, France) Hospices Civils de Lyon – Department of Biochemistry and Molecular Biology, Neurodegenerative Pathologies (Bron, France) Lyon Neurosciences Research Center (CNRS UMR 5292 / INSERM U1028) ETAP-Lab – Preclinical Efficacy CRO (Vandoeuvre-Lès-Nancy, France) Abstract: Neurodegenerative diseases, including Alzheimer’s disease (AD), present significant diagnostic challenges due to overlapping symptoms and the invasive, time-consuming, and costly nature